Haemonetics (HAE) Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Haemonetics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HAE shares.
View HAE analyst ratings or view top-rated stocks.

6 brokers have issued twelve-month price targets for Haemonetics' stock. Their HAE share price forecasts range from $88.00 to $115.00. On average, they predict the company's stock price to reach $103.17 in the next twelve months. This suggests a possible upside of 17.0% from the stock's current price.
View analysts price targets for HAE or view top-rated stocks among Wall Street analysts.

Haemonetics' stock was trading at $78.65 at the beginning of the year. Since then, HAE shares have increased by 12.1% and is now trading at $88.14.
View the best growth stocks for 2023 here.

Haemonetics saw a drop in short interest in April. As of April 30th, there was short interest totaling 1,040,000 shares, a drop of 21.2% from the April 15th total of 1,320,000 shares. Based on an average daily volume of 328,200 shares, the days-to-cover ratio is currently 3.2 days. Approximately 2.1% of the company's stock are sold short.
View Haemonetics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our HAE earnings forecast.

Haemonetics Co. (NYSE:HAE) released its quarterly earnings results on Tuesday, February, 7th. The medical instruments supplier reported $0.85 earnings per share for the quarter, beating analysts' consensus estimates of $0.79 by $0.06. The medical instruments supplier had revenue of $305.30 million for the quarter, compared to the consensus estimate of $300.47 million. Haemonetics had a net margin of 9.87% and a trailing twelve-month return on equity of 20.13%. Haemonetics's revenue for the quarter was up 17.5% on a year-over-year basis. During the same quarter last year, the firm earned $0.84 EPS.

ETFs with the largest weight of Haemonetics (NYSE:HAE) stock in their portfolio include SPDR S&P Health Care Equipment ETF (XHE), Invesco DWA Healthcare Momentum ETF (PTH), Invesco S&P MidCap Momentum ETF (XMMO), Harbor Health Care ETF (MEDI), Cultivar ETF (CVAR), First Trust Mid Cap Growth AlphaDEX Fund (FNY), First Trust Active Factor Mid Cap ETF (AFMC) and Fidelity Small-Mid Cap Opportunities ETF (FSMO).

Haemonetics updated its FY 2024 earnings guidance on Friday, May, 12th. The company provided earnings per share (EPS) guidance of $3.45-$3.75 for the period, compared to the consensus EPS estimate of $3.40. The company issued revenue guidance of $1.22 billion-$1.25 billion, compared to the consensus revenue estimate of $1.22 billion.

48 employees have rated Haemonetics Chief Executive Officer Christopher Simon on Glassdoor.com. Christopher Simon has an approval rating of 63% among the company's employees. This puts Christopher Simon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Haemonetics investors own include NVIDIA (NVDA), Micron Technology (MU), Johnson & Johnson (JNJ), AbbVie (ABBV), Citigroup (C), Align Technology (ALGN), Chipotle Mexican Grill (CMG), Netflix (NFLX) and Pfizer (PFE).

Haemonetics trades on the New York Stock Exchange (NYSE) under the ticker symbol "HAE."

Haemonetics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Wellington Management Group LLP (7.09%), Fisher Asset Management LLC (2.07%), Geode Capital Management LLC (1.87%), Royce & Associates LP (1.67%), Dimensional Fund Advisors LP (1.39%) and Boston Partners (1.32%). Insiders that own company stock include Anila Lingamneni, Christopher Simon, Dan Goldstein, Jacqueline Scanlan, Josep Llorens, Laurie A Miller, Mark W Kroll, Mark W Kroll, Michelle L Basil, Michelle L Basil, Richard J Meelia, Stewart W Strong and William P Mr Burke.
View institutional ownership trends.

Shares of HAE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of HAE stock can currently be purchased for approximately $88.14.

Haemonetics (NYSE:HAE) has a market capitalization of $4.45 billion and generates $1.17 billion in revenue each year. The medical instruments supplier earns $115.40 million in net income (profit) each year or $2.23 on an earnings per share basis.

The company employs 3,034 workers across the globe.

Haemonetics' mailing address is 125 Summer Street, Boston MA, 02110. The official website for the company is www.haemonetics.com. The medical instruments supplier can be reached via phone at (781) 848-7100, via email at gerry.gould@haemonetics.com, or via fax at 781-848-5106.